About us
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Our Strategic Road Map defines strategies, standards, and policy frameworks to support responsible global use of genomic and related health data.
Discover how a meeting of 50 leaders in genomics and medicine led to an alliance uniting more than 5,000 individuals and organisations to benefit human health.
GA4GH Inc. is a not-for-profit organisation that supports the global GA4GH community.
The GA4GH Council, consisting of the Executive Committee, Strategic Leadership Committee, and Product Steering Committee, guides our collaborative, globe-spanning alliance.
The Funders Forum brings together organisations that offer both financial support and strategic guidance.
The EDI Advisory Group responds to issues raised in the GA4GH community, finding equitable, inclusive ways to build products that benefit diverse groups.
Distributed across a number of Host Institutions, our staff team supports the mission and operations of GA4GH.
Curious who we are? Meet the people and organisations across six continents who make up GA4GH.
More than 500 organisations connected to genomics — in healthcare, research, patient advocacy, industry, and beyond — have signed onto the mission and vision of GA4GH as Organisational Members.
These core Organisational Members are genomic data initiatives that have committed resources to guide GA4GH work and pilot our products.
This subset of Organisational Members whose networks or infrastructure align with GA4GH priorities has made a long-term commitment to engaging with our community.
Local and national organisations assign experts to spend at least 30% of their time building GA4GH products.
Anyone working in genomics and related fields is invited to participate in our inclusive community by creating and using new products.
Wondering what GA4GH does? Learn how we find and overcome challenges to expanding responsible genomic data use for the benefit of human health.
Study Groups define needs. Participants survey the landscape of the genomics and health community and determine whether GA4GH can help.
Work Streams create products. Community members join together to develop technical standards, policy frameworks, and policy tools that overcome hurdles to international genomic data use.
GIF solves problems. Organisations in the forum pilot GA4GH products in real-world situations. Along the way, they troubleshoot products, suggest updates, and flag additional needs.
NIF finds challenges and opportunities in genomics at a global scale. National programmes meet to share best practices, avoid incompatabilities, and help translate genomics into benefits for human health.
Communities of Interest find challenges and opportunities in areas such as rare disease, cancer, and infectious disease. Participants pinpoint real-world problems that would benefit from broad data use.
The Technical Alignment Subcommittee (TASC) supports harmonisation, interoperability, and technical alignment across GA4GH products.
Find out what’s happening with up to the minute meeting schedules for the GA4GH community.
See all our products — always free and open-source. Do you work on cloud genomics, data discovery, user access, data security or regulatory policy and ethics? Need to represent genomic, phenotypic, or clinical data? We’ve got a solution for you.
All GA4GH standards, frameworks, and tools follow the Product Development and Approval Process before being officially adopted.
Learn how other organisations have implemented GA4GH products to solve real-world problems.
Help us transform the future of genomic data use! See how GA4GH can benefit you — whether you’re using our products, writing our standards, subscribing to a newsletter, or more.
Help create new global standards and frameworks for responsible genomic data use.
Align your organisation with the GA4GH mission and vision.
Want to advance both your career and responsible genomic data sharing at the same time? See our open leadership opportunities.
Join our international team and help us advance genomic data use for the benefit of human health.
Share your thoughts on all GA4GH products currently open for public comment.
Solve real problems by aligning your organisation with the world’s genomics standards. We offer software dvelopers both customisable and out-of-the-box solutions to help you get started.
Learn more about upcoming GA4GH events. See reports and recordings from our past events.
Speak directly to the global genomics and health community while supporting GA4GH strategy.
Be the first to hear about the latest GA4GH products, upcoming meetings, new initiatives, and more.
Questions? We would love to hear from you.
Read news, stories, and insights from the forefront of genomic and clinical data use.
Attend an upcoming GA4GH event, or view meeting reports from past events.
See new projects, updates, and calls for support from the Work Streams.
Read academic papers coauthored by GA4GH contributors.
Listen to our podcast OmicsXchange, featuring discussions from leaders in the world of genomics, health, and data sharing.
Check out our videos, then subscribe to our YouTube channel for more content.
View the latest GA4GH updates, Genomics and Health News, Implementation Notes, GDPR Briefs, and more.
Discover all things GA4GH: explore our news, events, videos, podcasts, announcements, publications, and newsletters.
23 Jan 2025
Part one of this two-part Policy Brief discusses general considerations related to protecting children’s genomic and health data under the General Data Protection Regulation (GDPR). This brief is published as part of the GA4GH Health Data Sharing, Privacy, and Regulatory Forum’s work to explore laws and regulations that have an impact on genomic and related health data sharing.
By Michael J. S. Beauvais
Today’s children have data generated about almost all aspects of their lives. At birth, the medical record includes the results of newborn screening (NBS) programmes that search for asymptomatic children at risk for treatable conditions. In the future, NBS will increasingly be collecting genomic data for those purposes.
These data pose important questions about the child’s privacy and about data governance more broadly. Children have privacy rights in international human rights law under the Convention on the Rights of the Child and the International Covenant on Civil and Political Rights, in regional law under instruments such as the Charter of Fundamental Rights of the European Union, and further specified in national (domestic) data protection laws like the European Union’s General Data Protection Regulation (GDPR), the US’s Health Insurance Portability and Accountability Act (HIPAA), Canada’s federal Personal Information Protection and Electronic Documents Act (PIPEDA), and so on.
Focusing on the GDPR, part one of this brief details certain fundamental aspects of processing children’s personal data for genomic and health-related research purposes. Part two of this brief will discuss issues regarding lawful bases for data processing and children.
Let us first address the question of who is a child according to the GDPR. Under the GDPR, a child is a minor — a person who is younger than the age of majority as specified in national law. Thus even a “competent” or “mature” minor (i.e. a child who demonstrates sufficient rational capacities for a specific decision) remains a child for GDPR purposes. The picture is a bit more complicated as additional rules may apply with different legal bases (see the next brief).
If there is a general rule for children’s data protection, it is that greater safeguards and care are required throughout the data processing lifecycle. The fact that one is processing children’s data implicates various obligations under the GDPR.
Best interests of the child
The best interests of the child is meant to guide decision-making when there are multiple ways to further a child’s rights and when there might be a conflict among the child’s rights (e.g. health versus privacy, health versus “being heard”). As is the case with the ethical design and conduct of research involving children, the best interests of the child should be a primary concern in all decisions in data processing.
A decision must be considered to be in the best interests of the child, which, according to the United Nations (UN) Committee on the Rights of the Child, is “adjusted and defined on an individual basis, according to the specific situation of the child or children concerned, taking into consideration their personal context, situation, and needs.” Building off of authoritative guidance from the UN Committee on the Rights of the Child, defining the way in which a child’s best interests are to be determined is a matter for national (domestic) law. The research team cannot make its own determination according to its own methodologies. While ethics may propose a particular way of understanding a child’s best interests, the starting point is national legislation, regulations, case law (judicial decisions), and other applicable laws that define the best interests. Failing that, looking to the Convention on the Rights of the Child and guidance from the UN Committee on the Rights of the Child are starting points. Depending on how open-ended the definition and likely included factors are, ethical understandings of the best interests may still play a role.
Children as vulnerable data subjects
The preamble to the GDPR indicates that children are vulnerable data subjects and that additional care is needed in processing their data. A number of concerns flow from this. Information given as part of a controller’s transparency obligations should be adapted to the child’s understanding. Likewise, any eventual code of conduct must specify how children’s data are handled and how the child’s legally authorised representatives are involved in consent.
Data protection authorities have demonstrated a willingness to take children’s vulnerability into consideration when interpreting and enforcing data protection law. For example, the Danish data protection supervisory authority has cited children’s vulnerability in its ordering of a municipality to stop using Google services in its primary schools. In a similar vein, the European Data Protection Board advises that Member States consider the child’s vulnerability when imposing restrictions on the right to object. Effectively, the consideration for a child’s vulnerability means that increased procedural, substantive, organisational, and technical safeguards are merited at every stage in the data processing lifecycle.
The GDPR recognises that children’s claims to either have their data rectified or deleted are more robust than those of adult data subjects, and in human genomic research, this is no different. The more robust claim to have data deleted poses questions about data retention. The question of retention can be a difficult one because hypothetically shorter retention may better suit the child’s privacy interests, but those data may be of significant scientific value, representing a unique point in time as the child undergoes many physiological changes. Nevertheless, the scientific or clinical utility of the data does not intrinsically justify retention: the data must be considered in relation to the purposes for which they are processed and the best interests of the child remain a primary consideration. For example, if phenotypic data are unique in time but wholly unrelated to the types of research for which data are processed, there is a lack of legal justification for retaining the data. The approach here works in tandem with the ethical right of a child to an “open future”, which aims to preserve a child’s ability to make meaningful decisions later in life when the child is not yet in a position to do so.
Further reading
Council of Europe -The best interests of the child – A dialogue between theory and practice (2016)
Relevant provisions
Convention on the Rights of the Child — articles 3, 12, 16
Charter of Fundamental Rights of the European Union — articles 7, 8, 24
General Data Protection Regulation — recitals 38, 58, 75; articles 12, 23, 40
Michael J. S. Beauvais is a doctoral candidate at the University of Toronto’s Faculty of Law.